Evergreen Therapeutics, Inc.

This study tests an experimental pill (EG-301) in 90 people with dry age-related macular degeneration (AMD) who have a specific type of vision loss called geographic atrophy. Participants will take either standard AREDS2 supplements alone or AREDS2 plus EG-301 daily for 6 months.…

This phase 3 trial tests whether adding the drug EG007 to a standard two-drug therapy (lenvatinib plus pembrolizumab) helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 adults whose cancer has returned after platinum che…

This early-stage trial tests a new medicine called EG-101 in 24 healthy women to make sure it is safe before trying it in pregnant women with severe pre-eclampsia, a dangerous condition that causes high blood pressure and can harm both mother and baby. The study gives a single do…

This study tests whether adding a drug called EG-007 to the standard combination of lenvatinib and pembrolizumab is safe for people with advanced or recurrent endometrial cancer. About 28 adults whose cancer has returned after platinum chemotherapy will take part. The goal is to …